Nanoparticle size influences the magnitude and quality of mucosal immune responses after intranasal immunization

Vaccine

Volumn 30, Issue 52, 2012, Pages 7541-7546

  Stano, Armando ^a   Nembrini, Chiara ^a   Swartz, Melody A ^a   Hubbell, Jeffrey A ^a   Simeoni, Eleonora ^a  

^a EPFL   (Switzerland)

Author keywords

Antigen delivery system; Immunoengineering; Mucosal vaccine; Nanoparticle; Particulate based adjuvant; Polyfunctional T cell

Indexed keywords

CPG OLIGODEOXYNUCLEOTIDE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; NANOCARRIER; NANOPARTICLE; OVALBUMIN; PROPYLENE; PROPYLENE SULFIDE NANOPARTICLE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN SPECIFICITY; ARTICLE; CD4 LYMPHOCYTE COUNT; FEMALE; HUMORAL IMMUNITY; IMMUNE RESPONSE; MOUSE; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL;

ADMINISTRATION, INTRANASAL; ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; DRUG CARRIERS; FEMALE; IMMUNITY, MUCOSAL; IMMUNIZATION; LUNG; MICE; MICE, INBRED C57BL; NANOPARTICLES; OVALBUMIN; VACCINES;

EID: 84870489032     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.10.050     Document Type: Article

References (34)

1. Holmgren J., Czerkinsky C. Mucosal immunity and vaccines. Nat Med 2005, 11:S45-S53.
2. Mitragotri S. Immunization without needles. Nat Rev Immunol 2005, 5:905-916.
3. Csaba N., Garcia-Fuentes M., Alonso M.J. Nanoparticles for nasal vaccination. Adv Drug Deliv Rev 2009, 61:140-157.
4. Neutra M.R., Kozlowski P.A. Mucosal vaccines: the promise and the challenge. Nat Rev Immunol 2006, 6:148-158.
5. Hubbell J.A., Thomas S.N., Swartz M.A. Materials engineering for immunomodulation. Nature 2009, 462:449-460.
6. Bachmann M.F., Jennings G.T. Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns. Nat Rev Immunol 2010, 10:787-796.
7. Petros R.A., DeSimone J.M. Strategies in the design of nanoparticles for therapeutic applications. Nat Rev Immunol 2010, 9:615-627.
8. Oyewumi M.O., Kumar A., Cui Z. Nano-microparticles as immune adjuvants: correlating particle sizes and the resultant immune responses. Expert Rev Vaccines 2010, 9:1095-1107.
9. Rehor A., Hubbell J.A., Tirelli N. Oxidation-sensitive polymeric nanoparticles. Langmuir 2005, 21:411-417.
10. van der Vlies A.J., O'Neil C.P., Hasegawa U., Hammond N., Hubbell J.A. Synthesis of pyridyl disulfide-functionalized nanoparticles for conjugating thiol-containing small molecules, peptides, and proteins. Bioconjug Chem 2010, 21:653-662.
11. Reddy S.T., Rehor A., Schmoekel H.G., Hubbell J.A., Swartz M.A. In vivo targeting of dendritic cells in lymph nodes with poly(propylene sulfide) nanoparticles. J Control Release 2006, 112:26-34.
12. Reddy S.T., van der Vlies A.J., Simeoni E., Angeli V., Randolph G.J., O'Neil C.P., et al. Exploiting lymphatic transport and complement activation in nanoparticle vaccines. Nat Biotechnol 2007, 25:1159-1164.
13. Stano A., van der Vlies A.J., Martino M.M., Swartz M.A., Hubbell J.A., Simeoni E. PPS nanoparticles as versatile delivery system to induce systemic and broad mucosal immunity after intranasal administration. Vaccine 2011, 29:804-812.
14. Nembrini C., Stano A., Dane K.Y., Ballester M., van der Vlies A.J., Marsland B.J., et al. Nanoparticle conjugation of antigen enhances cytotoxic T-cell responses in pulmonary vaccination. Proc Natl Acad Sci USA 2011, 108:E989-E997.
15. Hirosue S., Kourtis I.C., van der Vlies A.J., Hubbell J.A., Swartz M.A. Antigen delivery to dendritic cells by poly(propylene sulfide) nanoparticles with disulfide conjugated peptides: cross-presentation and T cell activation. Vaccine 2010, 28:7897-7906.
16. Ballester M., Nembrini C., Dhar N., de Titta A., de Piano C., Pasquier M., et al. Nanoparticle conjugation and pulmonary delivery enhance the protective efficacy of Ag85B and CpG against tuberculosis. Vaccine 2011, 29:6959-6966.
17. Seder R.A., Darrah P.A., Roederer M. T-cell quality in memory and protection: implications for vaccine design. Nat Rev Immunol 2008, 8:247-258.
18. Chono S., Tanino T., Seki T., Morimoto K. Uptake characteristics of liposomes by rat alveolar macrophages: influence of particle size and surface mannose modification. J Pharm Pharmacol 2007, 59:75-80.
19. He C., Hu Y., Yin L., Tang C., Yin C. Effects of particle size and surface charge on cellular uptake and biodistribution of polymeric nanoparticles. Biomaterials 2010, 31:3657-3666.
20. Foged C., Brodin B., Frokjaer S., Sundblad A. Particle size and surface charge affect particle uptake by human dendritic cells in an in vitro model. Int J Pharm 2005, 298:315-322.
21. Vallhov H., Gabrielsson S., Stromme M., Scheynius A., Garcia-Bennett A.E. Mesoporous silica particles induce size dependent effects on human dendritic cells. Nano Lett 2007, 7:3576-3582.
22. Manolova V., Flace A., Bauer M., Schwarz K., Saudan P., Bachmann M.F. Nanoparticles target distinct dendritic cell populations according to their size. Eur J Immunol 2008, 38:1404-1413.
23. Bachmann M.F., Rohrer U.H., Kundig T.M., Burki K., Hengartner H., Zinkernagel R.M. The influence of antigen organization on B cell responsiveness. Science 1993, 262:1448-1451.
24. Darrah P.A., Patel D.T., De Luca P.M., Lindsay R.W., Davey D.F., Flynn B.J., et al. Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nat Med 2007, 13:843-850.
25. Forbes E.K., Sander C., Ronan E.O., McShane H., Hill A.V., Beverley P.C., et al. Multifunctional, high-level cytokine-producing Th1 cells in the lung, but not spleen, correlate with protection against Mycobacterium tuberculosis aerosol challenge in mice. J Immunol 2008, 181:4955-4964.
26. Boaz M.J., Waters A., Murad S., Easterbrook P.J., Vyakarnam A. Presence of HIV-1 Gag-specific IFN-gamma+IL-2+ and CD28+IL-2+ CD4T cell responses is associated with nonprogression in HIV-1 infection. J Immunol 2002, 169:6376-6385.
27. Ciuffreda D., Comte D., Cavassini M., Giostra E., Buhler L., Perruchoud M., et al. Polyfunctional HCV-specific T-cell responses are associated with effective control of HCV replication. Eur J Immunol 2008, 38:2665-2677.
28. Millington K.A., Innes J.A., Hackforth S., Hinks T.S., Deeks J.J., Dosanjh D.P., et al. Dynamic relationship between IFN-gamma and IL-2 profile of Mycobacterium tuberculosis-specific T cells and antigen load. J Immunol 2007, 178:5217-5226.
29. Kotturi M.F., Botten J., Maybeno M., Sidney J., Glenn J., Bui H.H., et al. Polyfunctional CD4+ T cell responses to a set of pathogenic arenaviruses provide broad population coverage. Immun Res 2010, 6:4.
30. Plotkin S.A. Correlates of protection induced by vaccination. Clin Vaccine Immunol 2010, 17:1055-1065.
31. Fifis T., Gamvrellis A., Crimeen-Irwin B., Pietersz G.A., Li J., Mottram P.L., et al. Size-dependent immunogenicity: therapeutic and protective properties of nano-vaccines against tumors. J Immunol 2004, 173:3148-3154.
32. Gutierro I., Hernandez R.M., Igartua M., Gascon A.R., Pedraz J.L. Size dependent immune response after subcutaneous, oral and intranasal administration of BSA loaded nanospheres. Vaccine 2002, 21:67-77.
33. Katare Y.K., Muthukumaran T., Panda A.K. Influence of particle size, antigen load, dose and additional adjuvant on the immune response from antigen loaded PLA microparticles. Int J Pharm 2005, 301:149-160.
34. Mottram P.L., Leong D., Crimeen-Irwin B., Gloster S., Xiang S.D., Meanger J., et al. Type 1 and 2 immunity following vaccination is influenced by nanoparticle size: formulation of a model vaccine for respiratory syncytial virus. Mol Pharm 2007, 4:73-84.